Remdesivir in Very Old Patients (≥80 Years) Hospitalized with COVID-19: Real World Data from the SEMI-COVID-19 Registry.

Background: Large cohort studies of patients with COVID-19 treated with remdesivir have reported improved clinical outcomes, but data on older patients are scarce. Objective: This work aims to assess the potential benefit of remdesivir in unvaccinated very old patients hospitalized with COVID-19. Me...

Descripción completa

Detalles Bibliográficos
Autores: Ramos-Rincon, Jose-Manuel, López-Carmona, María-Dolores, Cobos-Palacios, Lidia, López-Sampalo, Almudena, Rubio-Rivas, Manuel, Martín-Escalante, María-Dolores, de-Cossio-Tejido, Santiago, Taboada-Martínez, María-Luisa, Muiño-Miguez, Antonio, Areses-Manrique, Maria, Martinez-Cilleros, Carmen, Tuñón-de-Almeida, Carlota, Abella-Vázquez, Lucy, Martínez-Gonzalez, Angel-Luís, Díez-García, Luis-Felipe, Ripper, Carlos-Jorge, Asensi, Víctor, Martinez-Pascual, Angeles, Guisado-Vasco, Pablo, Lumbreras-Bermejo, Carlos, Gómez-Huelgas, Ricardo, On Behalf Of The Semi-Covid-Network,
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/18688
Acceso en línea:http://hdl.handle.net/20.500.12105/18688
Access Level:acceso abierto
Palabra clave:COVID-19
SARS-CoV-2
Spain
Age ≥ 80
Mortality
Remdesivir
id ES_f6b63a3be9ffa40cbadab43dcf0287bb
oai_identifier_str oai:repisalud.isciii.es:20.500.12105/18688
network_acronym_str ES
network_name_str España
repository_id_str
spelling Remdesivir in Very Old Patients (≥80 Years) Hospitalized with COVID-19: Real World Data from the SEMI-COVID-19 Registry.Ramos-Rincon, Jose-ManuelLópez-Carmona, María-DoloresCobos-Palacios, LidiaLópez-Sampalo, AlmudenaRubio-Rivas, ManuelMartín-Escalante, María-Doloresde-Cossio-Tejido, SantiagoTaboada-Martínez, María-LuisaMuiño-Miguez, AntonioAreses-Manrique, MariaMartinez-Cilleros, CarmenTuñón-de-Almeida, CarlotaAbella-Vázquez, LucyMartínez-Gonzalez, Angel-LuísDíez-García, Luis-FelipeRipper, Carlos-JorgeAsensi, VíctorMartinez-Pascual, AngelesGuisado-Vasco, PabloLumbreras-Bermejo, CarlosGómez-Huelgas, RicardoOn Behalf Of The Semi-Covid-Network,COVID-19SARS-CoV-2SpainAge ≥ 80MortalityRemdesivirBackground: Large cohort studies of patients with COVID-19 treated with remdesivir have reported improved clinical outcomes, but data on older patients are scarce. Objective: This work aims to assess the potential benefit of remdesivir in unvaccinated very old patients hospitalized with COVID-19. Methods: This is a retrospective analysis of patients ≥ 80 years hospitalized in Spain between 15 July and 31 December 2020 (SEMI-COVID-19 Registry). Differences in 30-day all-cause mortality were adjusted using a multivariable regression analysis. Results: Of the 4331 patients admitted, 1312 (30.3%) were ≥80 years. Very old patients treated with remdesivir (n: 140, 10.7%) had a lower mortality rate than those not treated with remdesivir (OR (95% CI): 0.45 (0.29−0.69)). After multivariable adjustment by age, sex, and variables associated with lower mortality (place of COVID-19 acquisition; degree of dependence; comorbidities; dementia; duration of symptoms; admission qSOFA; chest X-ray; D-dimer; and treatment with corticosteroids, tocilizumab, beta-lactams, macrolides, and high-flow nasal canula oxygen), the use of remdesivir remained associated with a lower 30-day all-cause mortality rate (adjusted OR (95% CI): 0.40 (0.22−0.61) (p < 0.001)). Conclusions: Remdesivir may reduce mortality in very old patients hospitalized with COVID-19.20242024-02-2720222022-06-2920222022-06-29research articlehttp://purl.org/coar/resource_type/c_2df8fbb1VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articlehttp://hdl.handle.net/20.500.12105/18688reponame:Repisaludinstname:Instituto de Salud Carlos III (ISCIII)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repisalud.isciii.es:20.500.12105/186882026-06-12T12:43:37Z
dc.title.none.fl_str_mv Remdesivir in Very Old Patients (≥80 Years) Hospitalized with COVID-19: Real World Data from the SEMI-COVID-19 Registry.
title Remdesivir in Very Old Patients (≥80 Years) Hospitalized with COVID-19: Real World Data from the SEMI-COVID-19 Registry.
spellingShingle Remdesivir in Very Old Patients (≥80 Years) Hospitalized with COVID-19: Real World Data from the SEMI-COVID-19 Registry.
Ramos-Rincon, Jose-Manuel
COVID-19
SARS-CoV-2
Spain
Age ≥ 80
Mortality
Remdesivir
title_short Remdesivir in Very Old Patients (≥80 Years) Hospitalized with COVID-19: Real World Data from the SEMI-COVID-19 Registry.
title_full Remdesivir in Very Old Patients (≥80 Years) Hospitalized with COVID-19: Real World Data from the SEMI-COVID-19 Registry.
title_fullStr Remdesivir in Very Old Patients (≥80 Years) Hospitalized with COVID-19: Real World Data from the SEMI-COVID-19 Registry.
title_full_unstemmed Remdesivir in Very Old Patients (≥80 Years) Hospitalized with COVID-19: Real World Data from the SEMI-COVID-19 Registry.
title_sort Remdesivir in Very Old Patients (≥80 Years) Hospitalized with COVID-19: Real World Data from the SEMI-COVID-19 Registry.
dc.creator.none.fl_str_mv Ramos-Rincon, Jose-Manuel
López-Carmona, María-Dolores
Cobos-Palacios, Lidia
López-Sampalo, Almudena
Rubio-Rivas, Manuel
Martín-Escalante, María-Dolores
de-Cossio-Tejido, Santiago
Taboada-Martínez, María-Luisa
Muiño-Miguez, Antonio
Areses-Manrique, Maria
Martinez-Cilleros, Carmen
Tuñón-de-Almeida, Carlota
Abella-Vázquez, Lucy
Martínez-Gonzalez, Angel-Luís
Díez-García, Luis-Felipe
Ripper, Carlos-Jorge
Asensi, Víctor
Martinez-Pascual, Angeles
Guisado-Vasco, Pablo
Lumbreras-Bermejo, Carlos
Gómez-Huelgas, Ricardo
On Behalf Of The Semi-Covid-Network,
author Ramos-Rincon, Jose-Manuel
author_facet Ramos-Rincon, Jose-Manuel
López-Carmona, María-Dolores
Cobos-Palacios, Lidia
López-Sampalo, Almudena
Rubio-Rivas, Manuel
Martín-Escalante, María-Dolores
de-Cossio-Tejido, Santiago
Taboada-Martínez, María-Luisa
Muiño-Miguez, Antonio
Areses-Manrique, Maria
Martinez-Cilleros, Carmen
Tuñón-de-Almeida, Carlota
Abella-Vázquez, Lucy
Martínez-Gonzalez, Angel-Luís
Díez-García, Luis-Felipe
Ripper, Carlos-Jorge
Asensi, Víctor
Martinez-Pascual, Angeles
Guisado-Vasco, Pablo
Lumbreras-Bermejo, Carlos
Gómez-Huelgas, Ricardo
On Behalf Of The Semi-Covid-Network,
author_role author
author2 López-Carmona, María-Dolores
Cobos-Palacios, Lidia
López-Sampalo, Almudena
Rubio-Rivas, Manuel
Martín-Escalante, María-Dolores
de-Cossio-Tejido, Santiago
Taboada-Martínez, María-Luisa
Muiño-Miguez, Antonio
Areses-Manrique, Maria
Martinez-Cilleros, Carmen
Tuñón-de-Almeida, Carlota
Abella-Vázquez, Lucy
Martínez-Gonzalez, Angel-Luís
Díez-García, Luis-Felipe
Ripper, Carlos-Jorge
Asensi, Víctor
Martinez-Pascual, Angeles
Guisado-Vasco, Pablo
Lumbreras-Bermejo, Carlos
Gómez-Huelgas, Ricardo
On Behalf Of The Semi-Covid-Network,
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv
dc.subject.none.fl_str_mv COVID-19
SARS-CoV-2
Spain
Age ≥ 80
Mortality
Remdesivir
topic COVID-19
SARS-CoV-2
Spain
Age ≥ 80
Mortality
Remdesivir
description Background: Large cohort studies of patients with COVID-19 treated with remdesivir have reported improved clinical outcomes, but data on older patients are scarce. Objective: This work aims to assess the potential benefit of remdesivir in unvaccinated very old patients hospitalized with COVID-19. Methods: This is a retrospective analysis of patients ≥ 80 years hospitalized in Spain between 15 July and 31 December 2020 (SEMI-COVID-19 Registry). Differences in 30-day all-cause mortality were adjusted using a multivariable regression analysis. Results: Of the 4331 patients admitted, 1312 (30.3%) were ≥80 years. Very old patients treated with remdesivir (n: 140, 10.7%) had a lower mortality rate than those not treated with remdesivir (OR (95% CI): 0.45 (0.29−0.69)). After multivariable adjustment by age, sex, and variables associated with lower mortality (place of COVID-19 acquisition; degree of dependence; comorbidities; dementia; duration of symptoms; admission qSOFA; chest X-ray; D-dimer; and treatment with corticosteroids, tocilizumab, beta-lactams, macrolides, and high-flow nasal canula oxygen), the use of remdesivir remained associated with a lower 30-day all-cause mortality rate (adjusted OR (95% CI): 0.40 (0.22−0.61) (p < 0.001)). Conclusions: Remdesivir may reduce mortality in very old patients hospitalized with COVID-19.
publishDate 2022
dc.date.none.fl_str_mv 2022
2022-06-29
2022
2022-06-29
2024
2024-02-27
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/20.500.12105/18688
url http://hdl.handle.net/20.500.12105/18688
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:Repisalud
instname:Instituto de Salud Carlos III (ISCIII)
instname_str Instituto de Salud Carlos III (ISCIII)
reponame_str Repisalud
collection Repisalud
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869424787927859200
score 15,811543

Similares en LA Referencia